About Dr. Yared Hailemichael
Yared Hailemichael, PhD is an Assistant Professor at MD Anderson Cancer Center. He and his colleagues have made seminal contributions to cancer immunology in defining the regulation of CD8+ cytotoxic T cell tumor localization and tumor killing. He is continuing to work toward understanding and manipulating the anti-cancer immune response (Hailemichael et al., Nat Med. 2013 Apr 19; (4):465-72), an approach that is finally delivering real therapeutic benefit to patients with cancer. His recent work showed the key immunological mechanism that control cancer vaccine formulation synergy with CTLA-4, PD-(L)1 immune checkpoint blockade (ICB) therapy. Despite the immense promise of ICB therapy for cancer, immune-related adverse events (irAEs) are major limitations. Currently, he is investigating the specific cellular and molecular mechanism of these immune toxicities with implications not only for care of patients with cancer receiving ICB but may also provide critical insights into autoimmune disease. Dr. Hailemichael is a member of the Society for Immunotherapy of Cancer (SITC), American Association for Cancer Research (AACR) and Association for Cancer Immunotherapy (CIMT).
Assistant Professor, Department of Melanoma Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
|1998||Texas A&M University, College Station, TX, USA, PHD, Entomology|
|1992||Texas A&M University, College Station, TX, USA, MS, Entomology|
|1988||Addis Ababa University, Addis Ababa, Ethiopia, ETH, BS, Biology/Chemistry|
|2010-2013||Post doctoral fellowship, Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX|
Instructor, Department of Melanoma Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2018
Early Career Scientists committee member, Society for Immunotherapy of Cancer (SITC), Milwaukee, WI, 2015 - 2019
Consultant, 7Hills Pharma, Houston, TX, 2015 - Present
|2014||Travel grant award, SITC, Society for Immunotherapy of Cancer (SITC), National Harbor, MD|
|2013||Travel grant award, CIMT, Cancer Immunotherapy (CIMT), Mainz, Germany|
|2013||The Ben F. Love Fellowship award, University of Texas MD Anderson Cancer Center, Houston, TX|
- Hailemichael Y, Woods A, Fu T, He Q, Nielsen MC, Hasan F, Roszik J, Xiao Z, Vianden C, Khong H, Singh M, Sharma M, Faak F, Moore D, Dai Z, Anthony SM, Schluns KS, Sharma P, Engelhard VH, Overwijk WW. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. J Clin Invest 128(4):1338-1354, 2018. e-Pub 2018. PMID: 29480817.
- Zhang X, Baladandayuthapani V, Lin H, Kuiatse I, Shirazi F, Wang H, Jones R, Berkova Z, Lu J, Qian Y, Raina K, Coleman K, Crews C, Li B, Wang H, Hailemichael Y, Thomas S, Lee H, Wang Z, Davis R and Orlowski R. Protein Targeting Chimeric Molecules Specific for Bromodomain and Extra-terminal Motif Family Proteins are Active Against Pre-Clinical Models of Multiple Myeloma. Leukemia, 2018. PMID: 29581547.
- Haymaker CL, Hailemichael Y, Yang Y, Nurieva R. In Vivo Assay for Detection of Antigen-Specific T-cell Cytolytic Function using a Vaccination Model. J Vis Exp 129(e56255), 2017. e-Pub 2017. PMID: 29286361.
- Singh M, Vianden C, Cantwell MJ, Dai Z, Xiao Z, Sharma M, Khong H, Jaiswal AR, Faak F, Hailemichael Y, Janssen LME, Bharadwaj U, Curran MA, Diab A, Bassett RL, Tweardy DJ, Hwu P, Overwijk WW. Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. Nat Commun 8(1):1447, 2017. e-Pub 2017. PMID: 29129918.
- Ritthipichai K, Haymaker CL, Martinez M, Aschenbrenner A, Yi X, Zhang M, Kale C, Vence LM, Roszik J, Hailemichael Y, Overwijk WW, Varadarajan N, Nurieva R, Radvanyi LG, Hwu P, Bernatchez C. Multifaceted role of BTLA in the control of CD8+ T cell fate after antigen encounter. Clin Cancer Res 23(20):6151-6164, 2017. e-Pub 2017. PMID: 28754817.
- Sikora AG, Hailemichael Y, Overwijk WW. Conference scene: immune effector mechanisms in tumor immunity. Immunotherapy 4(2):141-3, 2012. PMID: 22339456.
- Hailemichael Y, Overwijk WW. Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard. Oncoimmunology 2(7):e24743, 2013. e-Pub 2013. PMID: 24073366.
- Hailemichael Y, Nielssen M, Faak F, Vanderslice P, Woodside DG, Market RV, Biediger RJ, Marathi UK, Overwijk WW. Integrin activator 7HP349 enhances anti-CTLA-4 antibody-based cancer therapy. Journal for Immunotherapy of Cancer, 2016.
- Hailemichael Y, Fu T, Woods A, Roszik J, Schluns KS, Engelhard VE, Sharma P, Overwijk WW. Effect of cancer vaccine formulation on synergy with anti-CTLA-4 and anti-PD-L1 checkpoint blockade therapy of cancer. Journal of Clinical Oncology, 2016.
- Hailemichael Y, Overwijk W. Peptide vaccines enhance checkpoint anti-melanoma therapeutic efficacy, 2015.
- Hailemichael Y. . Peptide/IFA emulsions limit tumor-specific CD8+ T cells tumor trafficking, 2013.
- Hailemichael Y., Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang X. et al. Persistent antigen at vaccination sites are graveyards for antigen specific CD8+ T cells, 2013.
- Hailemichael Y., Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang X. et al.. Persistent antigen at vaccination sites are graveyards for antigen specific CD8+ T cells, 2012.
- Hailemichael Y, Fu T, Woods A, Roszik J, Schluns KS, Engelhard VE, Sharma P, Overwijk WW. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. e-Pub 2017.
- Ya Z, Hailemichael Y, Overwijk W, Restifo NP. Mouse Model for Pre-clinical Study of Human Cancer Immunotherapy. In: Curr Protoc Immunol. 20.1, 1-20.1.42, 2015.
Letters to the Editor
- Hailemichael Y, Singh M and Overwijk W. Vaccinating with stem cells to stop cancer. Trends in Molecular Medicine 24: 524-526, 2018.
|Title:||Efficacy of Integrin Ligand Mimetic (ILM) Effect on Immune Checkpoint Inhibitors And Adoptive Therapy|
|Funding Source:||7 Hills Pharmaceuticals|
|Title:||Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer (phase I)|
|Title:||Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer (phase II)|